Indivior Leaps On Phase III Data For Depot Opioid Addiction Treatment

Indivior PLC is attempting to follow Braeburn Pharmaceuticals SPRL and Titan Pharmaceuticals Inc. down a new avenue for treating opioid addiction by using long-acting formulations of buprenorphine to improve treatment compliance. Braeburn/Titan's Probuphine implant was approved by the US FDA in May after what was a long and difficult path, and Indivior is looking to gaining approval of its product RBP-6000 on the back of new Phase III data by the end of next year.

Indivior's RBP-6000, which is designed to be used together with counselling and psychosocial support, is a "potentially transformational" treatment for...